Pembrolizumab and lenvatinib

Hi is anyone on the forum receiving immunotherapy with 

Pembrolizumab and lenvatinib for metastatic endometrial cancel which has spread to the lungs?

the research seems encouraging reference FYI

The combination of pembrolizumab and lenvatinib has emerged as an effective treatment for advanced, previously treated endometrial cancer. Pembrolizumab is an anti-programmed death 1 monoclonal antibody that blocks the interaction between programmed death 1 and programmed death ligands 1 and 2, and has been shown to be effective in the treatment of a variety of solid tumor types, including mismatch repair-deficient endometrial cancer. (https://ijgc.bmj.com/content/32/1/93)

Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479759/)

Pembrolizumab and lenvatinib, an oral multikinase inhibitor targeting vascular endothelial growth factor and platelet growth factor receptors, received accelerated approval by the FDA in 2019 for relapsed or advanced endometrial cancer that is not MMRd. (www.thelancet.com Vol 399 April 9, 2022).

I understand this is emerging therapy, NICE (https://www.nice.org.uk/guidance/indevelopment/gid-ta10692) will be discussing the results of its use at a committee meeting next month and will publish the results on the 4th of January 2023.